Pfizer Clarifies M&A Philosophy
This article was originally published in The Pink Sheet Daily
Pfizer's acquisition of Idun should not be viewed as a "departure" from the company's historical approach to mergers and acquisitions, Pfizer Senior VP-Science & Technology Peter Corr said in a letter to "The Pink Sheet" DAILY
You may also be interested in...
Pfizer is using its acquisition of Idun Pharmaceuticals as a new model for how it looks at M&A: allowing acquired companies to operate independently of Pfizer's big pharma machine
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.